TCF3::HLF-positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort
Identifying genetic mutations in rare childhood leukemia opens doors to targeted treatments beyond standard chemotherapy.
This is the largest single-center characterization of TCF3::HLF-positive B-ALL, a rare and aggressive leukemia subtype, identifying allo-HSCT as essential for durable remission. The study reveals high prevalence of RAS mutations and CD33 expression as potential therapeutic targets for this ultra-high-risk disease.
What the study was
- Study design
- Retrospective single-center cohort with integrated molecular analysis
- Population
- TCF3::HLF-positive B-ALL patients (N=34)
- Sample size
- 34
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- British Journal of Cancer
Why it surfaced
Largest molecular characterization of ultra-rare TCF3::HLF+ B-ALL identifying actionable targets (RAS, CD33). High unmet need in this subtype with historically near-zero survival.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.